OncoMatch/Clinical Trials/NCT05819892
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
Is NCT05819892 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Paclitaxel and Carboplatin for endometrial cancer.
Treatment: Paclitaxel · Carboplatin · Dostarlimab · Cisplatin — To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Disease stage
Required: Stage IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — staging (total hysterectomy and lymph node assessment)
Surgical staging is defined as total hysterectomy and lymph node assessment.
Cannot have received: anti-PD-1 therapy
Has received prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapeutic antibody or other similar agents.
Cannot have received: anti-PD-L1 therapy
Has received prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapeutic antibody or other similar agents.
Cannot have received: anti-CTLA-4 therapy
Has received prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapeutic antibody or other similar agents.
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dL; Platelets ≥ 100,000/mcl; ANC ≥ 1,500/mcl
Kidney function
Creatinine ≤ 2 x ULN or CrCl ≥60ml/min
Liver function
Bilirubin ≤ 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level ≤ 2 x ULN may be enrolled); ALT and AST ≤ 2.5 x ULN
Adequate hematologic function within 14 days prior to enrollment defined as follows: Hemoglobin ≥ 9 g/dL; Platelets ≥ 100,000/mcl; ANC ≥ 1,500/mcl. Adequate renal function within 14 days prior to enrollment defined as follows: Creatinine ≤ 2 x ULN or CrCl ≥60ml/min. Adequate hepatic function within 14 days prior to enrollment defined as follows: Bilirubin ≤ 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level ≤ 2 x ULN may be enrolled); ALT and AST ≤ 2.5 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify